BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10458249)

  • 1. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
    Boku N; Ohtsu A; Shimada Y; Shirao K; Seki S; Saito H; Sakata Y; Hyodo I
    J Clin Oncol; 1999 Jan; 17(1):319-23. PubMed ID: 10458249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
    Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
    Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.
    Yamao T; Ohta K; Ohyama S; Ishihara S; Chin K; Maruyama M; Takahashi T; Nakajima T
    Jpn J Clin Oncol; 2004 May; 34(5):255-61. PubMed ID: 15231860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
    Giuliani F; Molica S; Maiello E; Battaglia C; Gebbia V; Di Bisceglie M; Vinciarelli G; Gebbia N; Colucci G;
    Am J Clin Oncol; 2005 Dec; 28(6):581-5. PubMed ID: 16317268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.
    Yoshida M; Boku N; Ohtsu A; Muto M; Nagashima F; Yoshida S
    Gastric Cancer; 2001; 4(3):144-9. PubMed ID: 11760080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
    Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
    Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
    Nagahori Y; Nagahori K; Hamaguchi Y; Fukushima T; Masui H; Mogaki M; Abe T
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1555-9. PubMed ID: 18799911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
    Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
    Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
    Yoshida T; Yoshikawa T; Tsuburaya A; Kobayashi O; Hasegawa S; Osaragi T; Sairenji M
    Anticancer Res; 2006; 26(2B):1595-8. PubMed ID: 16619577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
    Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
    Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
    Im CK; Rha SY; Jeung HC; Ahn JB; Shin SJ; Noh SH; Roh JK; Chung HC
    Am J Clin Oncol; 2010 Feb; 33(1):56-60. PubMed ID: 19730355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.
    Lim WT; Lim ST; Wong NS; Koo WH
    J Chemother; 2003 Aug; 15(4):400-5. PubMed ID: 12962370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
    Hu B; Yu JR; Wen ZZ; Shu YQ; Wang BC; Yin HR; Chen L; Bai YX; Liang J; Chen L; Cheng Y; Shen L; Zhou Y; Zhang HG; Li J; Wan DS; Chen S; Jia TZ; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):940-3. PubMed ID: 19173999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.
    Shen WC; Yang TS; Hsu HC; Chen JS
    Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
    Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
    Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.